Block Grant R03CA115062

The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...

Federal Grant Award Summary Xgenomes Corp. received a $399,816 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning September 1, 2025, and concluding August 31, 2026. The company will develop a novel circulating tumor DNA (ctDNA) analysis platform that directly measures both genetic mutations and methylation changes with accuracy exceeding current next-generation sequencing methods by over 100-fold. The technology...

This Project Grant from the National Institutes of Health's National Cancer Institute totaling $668,151 will support the development of highly multiplexed live-cell G protein-coupled receptor (GPCR) arrays for glioma drug discovery. Spectragenetics, Inc. will deploy an automated multiplexed live-cell assay to detect and quantify agonist and inverse-agonist activities against 55 GPCRs known to be upregulated or downregulated in human gliomas. The assay will be used to screen 48 established...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Cereus Diagnostics Corp. $764,448 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test for detecting clinically actionable lung cancer mutations. The three-year project, effective August 1, 2025 through July 31, 2028, will deliver a clinical-grade...

This Project Grant award, funded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program, supports research investigating the effects of ultraviolet radiation (UVR) exposure on chromatin structure and gene expression in melanocytes, which are the origin of cutaneous malignant melanoma. The $156,250 award, granted to the University of Toledo Health Science Campus, aims to elucidate how the loss of the BRG1 chromatin remodeling...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

The National Cancer Institute (NCI) awarded a $425,772 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to conduct an epidemiologic study on the association between microplastic pollution in bronchoalveolar lavage fluid and lung cancer. The award period runs from July 15, 2024 to June 30, 2026. The study aims to investigate the prevalence and potential health impacts of microplastic exposure in the...

Federal Cooperative Agreement Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $225,511 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 16, 2026, with a completion date of February 29, 2028. The award supports the development and validation of a plasma-based multimodal digital polymerase chain reaction (PCR) assay to detect androgen receptor (AR) somatic...

The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...

The Sloan-Kettering Institute for Cancer Research received a $789,739 Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), effective September 19, 2025, through August 31, 2029. This award supports the development of experimental and computational tools to transform Perturb-Seq into a platform for rationally engineering cellular transcriptional states in fibroblasts and other differentiated cell types. The research...